Abstract
Serum lactate dehydrogenase (LDH) concentrations correlate with tumor progression and poor outcome. We evaluated the predictive value of serum LDH level for overall survival (OS) of patients with advanced pancreatic cancer after gemcitabine-based chemotherapy. We retrospectively enrolled 364 patients with locally advanced or metastatic pancreatic adenocarcinoma who were then allocated to training (n = 139) and validation cohorts (n = 225). We evaluated the association between serum LDH levels and OS as well as with markers of systemic inflammation, including neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR) and lymphocyte/monocyte ratio (LMR). Kaplan–Meier analyses revealed that low serum LDH levels in the training cohort significantly correlated with longer OS. Multivariate analysis identified the serum LDH levels as an independent prognostic predictor of OS (p = 0.005). Serum LDH levels correlated positively with NLR and PLR and correlated negatively with LMR. Similar results were obtained for the validation cohort, except that multivariate analysis identified the serum LDH level as a significant prognostic predictor and only a statistical trend for OS (p = 0.059). We conclude that serum LDH levels were associated with the systemic inflammatory response and served as a significant prognostic predictor of OS. Serum LDH levels predicted OS in patients with advanced pancreatic cancer after gemcitabine-based palliative chemotherapy.
Highlights
Useful for monitoring pathologically diagnosed disease, their levels increase in patients with benign pancreatic disease (BPD)[8,9]
Hypoxia and systemic inflammation are associated with the advanced stages of pancreatic cancer, and serum LDH levels serve as an indirect marker of tumour hypoxia
We investigated the correlation between LDH levels and the prognosis of patients with advanced pancreatic cancer after they were administered gemcitabine-based palliative chemotherapy
Summary
Useful for monitoring pathologically diagnosed disease, their levels increase in patients with benign pancreatic disease (BPD)[8,9]. We focused our attention on the prognostic value of serum LDH levels in patients with advanced pancreatic cancer after they were administered gemcitabine-based palliative chemotherapy. The prognostic value of serum LDH levels in patients with advanced pancreatic cancer after they are administered gemcitabine-based palliative chemotherapy is unknown. The correlation between the systemic inflammation and serum LDH level has not been evaluated in patients with pancreatic cancer after they are administered gemcitabine-based palliative chemotherapy. To address these questions, here we evaluated the independent prognostic significance of serum LDH levels and their potential associations with cancer-specific survival and the systemic inflammationin a large cohort of such patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
